<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04188574</url>
  </required_header>
  <id_info>
    <org_study_id>BBTAF202</org_study_id>
    <nct_id>NCT04188574</nct_id>
  </id_info>
  <brief_title>A Trial Involving Treatment of BB2603 in Subjects With Distal Subungual Onychomycosis of the Toenail</brief_title>
  <official_title>A Multi-Centre, International, Randomised, Vehicle Controlled, Parallel-Group, Double-Blinded Phase 2 Trial of BB2603 Topical Treatment in Subjects With Distal Subungual Onychomycosis (DSO) of the Toenail</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Blueberry Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>IQVIA Biotech</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Blueberry Therapeutics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will be a multicenter, international, randomized, vehicle-controlled,&#xD;
      parallel-group, double-blinded study. Subjects who are eligible to participate with a&#xD;
      confirmed diagnosis of Distal Subungual onychomycosis (DSO) of the toenail will be randomized&#xD;
      and participate in one of the following treatment groups: BB2603-1: 0.01% terbinafine/0.03%&#xD;
      polyhexanide formulation, or BB2603-3: 0.03% terbinafine/0.09% polyhexanide formulation, or&#xD;
      BB2603-10: 0.1% terbinafine/0.3% polyhexanide formulation, or Vehicle: 0.3% polyhexanide/20%&#xD;
      ethanol/water formulation. The subject in each treatment group will be treated twice daily&#xD;
      (BID) for 12 weeks and then complete a 28-day post-treatment visit.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Onychomycosis (OM; fungal nail infection) is a common and contagious fungal infection of the&#xD;
      nail plate or nail bed, leading to the gradual destruction of the nail plate. OM is&#xD;
      considered the most prevalent of the nail ailments, accounting for about 50% of all diseased&#xD;
      nails and about 30% of cutaneous fungal infections. The prevalence of OM is reported to be&#xD;
      23% across Europe, 13.8% in North America and approximately 10% in Japan, with the prevalence&#xD;
      increasing in Western countries, presumably due to lifestyle changes and the ageing of the&#xD;
      population.&#xD;
&#xD;
      Distal subungual onychomycosis (DSO) is the most common form of OM, characterised by invasion&#xD;
      of the nail bed and underside of the nail plate beginning at the hyponychium. This infection&#xD;
      is visualised as nails with normal surface texture and thickness but variable &quot;bays&quot; of white&#xD;
      nail that extend from the distal nail tip proximally into the area of the nail bed. The vast&#xD;
      majority of cases of OM are caused by dermatophyte fungi. In 80% to 98% of affected&#xD;
      individuals, Trichophyton rubrum with additional infections caused by Trichophyton&#xD;
      mentagrophytes var interdigitale (commonly referred to as Trichophyton mentagrophytes) or&#xD;
      Epidermophyton floccosum. The dermatophyte Trichophyton rubrum is the major cause of tinea&#xD;
      pedis (TP; athlete's foot) and OM. OM is a progressive disease; if left untreated, OM can&#xD;
      lead to permanent nail damage and associated discomfort.&#xD;
&#xD;
      Onychomycosis is currently treated with surgery, medical devices (eg laser therapy), oral or&#xD;
      topical anti-fungal agents or a combination of both. Oral terbinafine, when used for a&#xD;
      minimum of 3 months, can achieve an efficacy of 38% or higher if treatment is extended but&#xD;
      has a significant drug-interaction and side effect profile, including liver failure, and&#xD;
      periodic monitoring (after 4-6 weeks of treatment) of liver function test is recommended.&#xD;
      Topical agents are used for up to 18 months but have significantly lower efficacy rates of&#xD;
      less than 20%.&#xD;
&#xD;
      Terbinafine is a well-established synthetic allylamine anti-fungal developed by Sandoz (now&#xD;
      Novartis) and commercially available worldwide for more than 25 years in different oral and&#xD;
      topical formulations as a dermal cream (1%), emulsion gel (1%), solution/spray (1%), as well&#xD;
      as oral tablets (250 mg and 125 mg). It is highly hydrophobic in nature and tends to&#xD;
      accumulate in skin, nails, and fatty tissues. Terbinafine's anti-fungal mechanism of action&#xD;
      is by inhibition of squalene epoxidase in the fungal cell membrane. This leads to a&#xD;
      deficiency in ergosterol and an intracellular accumulation of squalene, resulting in fungal&#xD;
      cell rupture/lysis (fungicidal activity).&#xD;
&#xD;
      Dermatophytoses of nails, in contrast to those at other body sites, are particularly&#xD;
      difficult to eradicate with drug treatment. This is the consequence of factors intrinsic to&#xD;
      the nail (the hard, protective nail plate, sequestration of pathogens between the nail bed&#xD;
      and plate, and slow growth of the nail). The unique barrier properties of the nail plate,&#xD;
      which hampers the passage of anti-fungal drugs in a concentration required to eradicate the&#xD;
      deeply-seated causative fungi in the nail bed, is a specific challenge.&#xD;
&#xD;
      As such, there is a recognized need for a simple, effective and curative topical treatment&#xD;
      for OM. Furthermore, topical treatment may result in minimal adverse systemic events and&#xD;
      possibly improved adherence.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 22, 2021</start_date>
  <completion_date type="Anticipated">August 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Double-Blinded</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Treatment allocation will not be disclosed to the site team or subject or the clinical Sponsor team.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Number of subjects with an Early Response for BB2603-10 versus vehicle</measure>
    <time_frame>16 weeks</time_frame>
    <description>Early Response is defined as clinimetrically assessed clear nail growth (yes/no) and/or negative dermatophyte culture (yes/no).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with a Complete Cure for BB2603-10 versus vehicle</measure>
    <time_frame>52 weeks</time_frame>
    <description>Complete Cure is assessed programmatically and is defined as satisfying the following: binary (yes/no) completely clear nail and mycological response (negative KOH and negative dermatophyte culture).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with Completely Clear Nail, Almost Clear Nail, Negative KOH or Negative Dermatocyte Culture, assessed separately, for BB2603-10 versus vehicle</measure>
    <time_frame>52 weeks</time_frame>
    <description>Completely Clear Nail (yes/no), Almost Clear Nail (yes/no), Negative KOH (yes/no) and Negative Dermatocyte Culture (yes/no) are each assessed separately</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration of terbinafine in the plasma in all subjects</measure>
    <time_frame>52 weeks</time_frame>
    <description>Terbinafine, the active component of BB2603, will be measured in pg/ml</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with adverse events</measure>
    <time_frame>16, 24, 28 weeks</time_frame>
    <description>Safety and tolerability data will be assessed by number of subjects with adverse events (AEs), serious adverse events, drug discontinuations due to AEs, and deaths. Data will be assessed at Week 16, 24 and 28 .</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with an Early Response for BB2603-1 or BB2603-3, respectively versus vehicle</measure>
    <time_frame>16 weeks</time_frame>
    <description>Early Response is defined as clinimetrically assessed clear nail growth (yes/no) and/or negative dermatophyte culture (yes/no).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with a Complete Cure for BB2603-1 or BB2603-3, respectively versus vehicle</measure>
    <time_frame>52 weeks</time_frame>
    <description>Complete Cure is assessed programmatically and is defined as satisfying the following: binary (yes/no) completely clear nail and mycological response (negative KOH and negative dermatophyte culture).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with Completely Clear Nail, Almost Clear Nail, Negative Dermatocyte Culture or Negative Dermatophyte Culture, assessed separately for BB2603-1 or BB2603-3, respectively versus vehicle</measure>
    <time_frame>52 weeks</time_frame>
    <description>Completely Clear Nail (yes/no), Almost Clear Nail (yes/no), Negative KOH (yes/no) and Negative Dermatocyte Culture (yes/no) are each assessed separately</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">220</enrollment>
  <condition>Distal Subungual Onychomycosis</condition>
  <condition>Fungal Infection</condition>
  <condition>Fungus, Nail</condition>
  <arm_group>
    <arm_group_label>BB2603-10</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment with topical spray twice-daily (BID) BB2603-10: 0.1% terbinafine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BB2603-3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment with topical spray twice-daily (BID) BB2603-3: 0.03% terbinafine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BB2603-1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment with topical spray twice-daily (BID)BB2603-1: 0.01% terbinafine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BB2603-1</intervention_name>
    <description>Treatment with topical spray twice-daily (BID) BB2603-1: 0.01% terbinafine</description>
    <arm_group_label>BB2603-1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BB2603-3</intervention_name>
    <description>Treatment with topical spray twice-daily (BID) BB2603-3: 0.03% terbinafine</description>
    <arm_group_label>BB2603-3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BB2603-10</intervention_name>
    <description>Treatment with topical spray twice-daily (BID) BB2603-10: 0.1% terbinafine</description>
    <arm_group_label>BB2603-10</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vehicle</intervention_name>
    <description>0.3% polyhexanide/20% ethanol/water.</description>
    <arm_group_label>BB2603-1</arm_group_label>
    <arm_group_label>BB2603-10</arm_group_label>
    <arm_group_label>BB2603-3</arm_group_label>
    <other_name>polyaminopropyl biguanide polyhexanide</other_name>
    <other_name>polyhexamethylene biguanide</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female ≥18 (and ≤99) at the time of Informed Consent.&#xD;
&#xD;
          2. Clinically and mycologically (KOH and culture positive for dermatophytes [microbial&#xD;
             infection with fungus belonging to the genus Trichophyton, Microsporum,&#xD;
             Epidermophyton]) confirmed diagnoses of DSO of the target toenail affecting ≥25% to&#xD;
             ≤60% of the target toenail as determined through clinimetric measurement.&#xD;
&#xD;
          3. Signed written informed consent form (ICF) prior to any trial related activity&#xD;
             (subjects must have the mental, literate, and legal ability to give a written informed&#xD;
             consent, which must comply with the ICH GCP guidelines and local requirements).&#xD;
&#xD;
          4. Subjects must be willing and able to comply with trial requirements.&#xD;
&#xD;
          5. Females must be either postmenopausal for ≥1 year (ie 12 consecutive months of&#xD;
             amenorrhea, for which there is no other obvious pathologic or physiologic cause), or&#xD;
             surgically sterile (tubal ligation, hysterectomy, or bilateral oophorectomy) for at&#xD;
             least 6 months or, if of childbearing potential must use either highly effective birth&#xD;
             control methods such as:&#xD;
&#xD;
               -  Oral, intravaginal or transdermal oestrogen- and progestogen-containing hormonal&#xD;
                  contraception associated with inhibition of ovulation&#xD;
&#xD;
               -  Oral, injectable or implantable progestogen-only hormonal contraception&#xD;
                  associated with inhibition of ovulation&#xD;
&#xD;
               -  Intrauterine device or intrauterine hormone-releasing system&#xD;
&#xD;
               -  Bilateral tubal occlusion&#xD;
&#xD;
               -  Vasectomised partner provided that the partner is the sole sexual partner and&#xD;
                  that the vasectomised partner has received medical assessment of the surgical&#xD;
                  success Clinical Study Protocol&#xD;
&#xD;
               -  Sexual abstinence, ie, refraining from heterosexual intercourse during the entire&#xD;
                  period of risk associated with the trial treatments&#xD;
&#xD;
        OR&#xD;
&#xD;
        Acceptable birth control methods such as:&#xD;
&#xD;
          -  Progestogen-only oral hormonal contraception, where inhibition of ovulation is not the&#xD;
             primary mode of action&#xD;
&#xD;
          -  Male or female condom with or without spermicide&#xD;
&#xD;
          -  Cap, diaphragm or sponge with spermicide&#xD;
&#xD;
          -  A combination of male condom with either cap, diaphragm or sponge with spermicide&#xD;
             (double barrier methods) are also considered acceptable birth control methods&#xD;
&#xD;
        while using trial medication and 28 days after last dose of IMP.&#xD;
&#xD;
        Birth control methods which are considered unacceptable: Periodic abstinence (calendar,&#xD;
        symptothermal, post-ovulation methods), withdrawal (coitus interruptus), spermicides only,&#xD;
        and lactational amenorrhoea method. Female condom and male condom should not be used&#xD;
        together.&#xD;
&#xD;
        Treatment with the IMP will be interrupted in case of pregnancy.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Any other form of OM except DSO.&#xD;
&#xD;
          2. Nails with clinical evidence of no or low distal growth.&#xD;
&#xD;
          3. DSO of the target toenail where involvement has extended into the proximal portion of&#xD;
             the target nail (unaffected proximal nail is ≤3mm) or nail matrix.&#xD;
&#xD;
          4. Estimated target toenail thickness &gt;3mm.&#xD;
&#xD;
          5. Presence of dermatophytoma (defined as thick masses of fungal hyphae and necrotic&#xD;
             keratin between the nail plate and nail bed) on the target nail.&#xD;
&#xD;
          6. History of dermatophyte infections unresponsive to systemic or topical anti-fungal&#xD;
             drugs (other than OM).&#xD;
&#xD;
          7. Presence of toenail infection that does not involve a dermatophyte.&#xD;
&#xD;
          8. Presence of toenail infection that involves a non-dermatophyte fungus or yeast, either&#xD;
             alone or in combination with a dermatophyte, or any other infection (eg bacterial).&#xD;
&#xD;
          9. Topical treatment with an antifungal medication within 12 weeks before&#xD;
             Randomisation/Visit 2 (with the exception of up to 2 weeks' treatment during the&#xD;
             screening period with a non-terbinafine topical antifungal to treat clinically active&#xD;
             TP).&#xD;
&#xD;
             Other exclusion criteria&#xD;
&#xD;
         10. Systemic use of anti-fungal treatment within 12 months before Randomisation/Visit 2.&#xD;
&#xD;
         11. Past use within the last 6 months before Randomisation/Visit 2 or planned use of laser&#xD;
             therapy, photodynamic therapy, chemical, surgical, relevant mechanical removal for OM&#xD;
             or debridement.&#xD;
&#xD;
         12. Concomitant clinically suspected active TP at Randomisation/Visit 2.&#xD;
&#xD;
         13. Known allergy or known intolerabilities to any of the tested treatment products.&#xD;
&#xD;
         14. Subjects with diabetes, immune suppression, peripheral vascular disease, lymphatic&#xD;
             insufficiency, recurrent cellulitis, or other compromised states of health whether due&#xD;
             to underlying medical disorders or to long-term immunosuppressive treatments&#xD;
             (including &gt;4 weeks systemic corticoids or &gt;4 weeks topical corticoids on the feet).&#xD;
             Topical immunosuppressive treatment if not on the target nail is allowed.&#xD;
&#xD;
         15. Females of childbearing potential with a positive serum pregnancy test at&#xD;
             Screening/Visit 1 and/or a positive urine pregnancy test at Randomisation/Visit 2 are&#xD;
             excluded.&#xD;
&#xD;
         16. Women of childbearing potential who are pregnant or breast feeding or who plan to&#xD;
             become pregnant after enrolment until 28 days after the last dose of IMP.&#xD;
&#xD;
         17. Subjects previously randomised in this trial or received BB2603 previously.&#xD;
&#xD;
         18. Use of any investigational agent during the study or within 28 days or 5 half-lives&#xD;
             prior to Randomisation/Visit 2, whichever is longer.&#xD;
&#xD;
         19. Close affiliation with the Investigator (eg, a close relative) or persons working at a&#xD;
             trial site, or subject who is an employee of the Sponsor's company.&#xD;
&#xD;
         20. Subjects who are institutionalised because of legal or regulatory order.&#xD;
&#xD;
         21. Hepatic impairment with AST or ALT &gt;5 x Upper Limit of Normal.&#xD;
&#xD;
         22. Estimated creatinine clearance using Cockcroft-Gault formula and actual body weight&#xD;
             &lt;30 ml/min.&#xD;
&#xD;
         23. Presence of any other condition or infection of the foot or nail or other disease&#xD;
             process that might affect the safety and well-being of the subject or confound the&#xD;
             treatment evaluation (eg, psoriasis, lichen planus, or other medical conditions known&#xD;
             to induce nail changes, trauma, previous toenail surgery with any residual&#xD;
             disfigurement or any dermatological or nail condition that could mimic the signs and&#xD;
             symptoms of OM, signs of severe peripheral circulatory insufficiency, use of chronic&#xD;
             immunosuppressive medication or radiation therapy within 2 months prior to trial entry&#xD;
             or planned during the trial period, immunocompromised).&#xD;
&#xD;
         24. Subjects deemed to be at risk of re-infection or recurrence of OM due to occupational,&#xD;
             environmental or behavioural lifestyle in the opinion of the Investigator.&#xD;
&#xD;
         25. Any other significant disease or disorder which, in the opinion of the Investigator,&#xD;
             may either put the subject at risk because of participation in this trial, or may&#xD;
             influence the result of the trial, or the subject's availability to participate in the&#xD;
             trial.&#xD;
&#xD;
         26. Any known or suspected hypersensitivity to, or known allergy to, or other&#xD;
             intolerability to BB2603 or its active ingredient or excipients.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Attila Timar-Peregrin, MD, PhD, DVProf</last_name>
    <phone>+36 30 268 0190</phone>
    <email>attila.timar-peregrin@novellaclinical.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>CTCenter MaVe</name>
      <address>
        <city>Olomouc</city>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Sanatorium prof. Arenbergera</name>
      <address>
        <city>Prague</city>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Petr Arenberger</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dermatovenerologická klinika VFN</name>
      <address>
        <city>Praha</city>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ivana Kuklová</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Licca Clinical Research Institute</name>
      <address>
        <city>Augsburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Georg Popp</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Praxis Dr. med. Thomas Wildfeuer &amp; Kolleg*innen</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Wildfeuer</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hautzentrum Jahrhunderthaus Gemeinschaftspraxis Dres. Niesmann und Othlinghaus</name>
      <address>
        <city>Bochum</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Johannes Niesmann</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Uniklink Carl Gustav Carus, Klinik und Polyklinik für Dermatologie</name>
      <address>
        <city>Dresden</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrea Bauer</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Pro Derma Studieninstitut</name>
      <address>
        <city>Dülmen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Hautarztpraxis Dres. Leitz</name>
      <address>
        <city>Stuttgart</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicolas Leitz</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centroderm GmbH</name>
      <address>
        <city>Wuppertal</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Dirschka</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>NZOZ Dermal</name>
      <address>
        <city>Białystok</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adam Wronski</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>NZOZ Osteo-Medic</name>
      <address>
        <city>Białystok</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Malgorzata Janczylo-Jankowska</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinika Dermatologii, Wenerologii</name>
      <address>
        <city>Gdańsk</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roman Nowicki</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centrum Medyczne Angelius Provita</name>
      <address>
        <city>Katowice</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Magdalena Kolanko</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Gyncentrum Osrodek Badan Klinicznych</name>
      <address>
        <city>Katowice</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marcin Zakrzewski</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Etg Lublin Kunickiego</name>
      <address>
        <city>Lublin</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anna Glowacka</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>KO-MED Centra Kliniczne Lublin II Polish</name>
      <address>
        <city>Lublin</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>ETG Siedlce</name>
      <address>
        <city>Siedlce</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Magdalena Dmowska-Stecewicz</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>ETG Skierniewice</name>
      <address>
        <city>Skierniewice</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Laser Clinic</name>
      <address>
        <city>Szczecin</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katarzyna Turek- Urasinska</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>ETG Warszawa</name>
      <address>
        <city>Warszawa</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Zegadło- Mylik</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CITYCLINIC Przychodnia Lekarsko</name>
      <address>
        <city>Wrocław</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>dermMedica</name>
      <address>
        <city>Wrocław</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jolanta Weglowska</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>ETG Zamość</name>
      <address>
        <city>Zamość</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Beata Bełz- Łagoda</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>ETG Lodz</name>
      <address>
        <city>Łódź</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Barbara Kaźmierczak- Tracz</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Czechia</country>
    <country>Germany</country>
    <country>Poland</country>
  </location_countries>
  <link>
    <url>http://www.medicines.org.uk/emc/medicine/1290/SPC/Lamisil+Tablets+250mg</url>
    <description>Lamisil SmPC: Lamisil Tablets 250 mg Summary of Product Characteristics. Novartis Pharmaceuticals UK Limited. 03 January 2017. Accessed on 06 December 2017. Available at:</description>
  </link>
  <link>
    <url>http://www.medicines.org.uk/emc/medicine/21035</url>
    <description>Lamisil SmPC: Lamisil AT 1% Spray Summary of Product Characteristics. GlaxoSmithKline Consumer Healthcare (UK) Trading Limited. 23 March 2016. Accessed on 06 December 2017. Available at:</description>
  </link>
  <reference>
    <citation>Butcher M. PHMB: an effective antimicrobial in wound bioburden management. Br J Nurs. 2012 Jun 28-Jul 11;21(12):S16, S18-21.</citation>
    <PMID>22875372</PMID>
  </reference>
  <reference>
    <citation>Chouhan P, Saini TR. Hydroxypropyl- β -cyclodextrin: A Novel Transungual Permeation Enhancer for Development of Topical Drug Delivery System for Onychomycosis. J Drug Deliv. 2014;2014:950358. doi: 10.1155/2014/950358. Epub 2014 Aug 6.</citation>
    <PMID>25177500</PMID>
  </reference>
  <reference>
    <citation>Crawford F. Athlete's foot. BMJ Clin Evid. 2009 Jul 20;2009. pii: 1712. Review.</citation>
    <PMID>21696646</PMID>
  </reference>
  <reference>
    <citation>Darkes MJ, Scott LJ, Goa KL. Terbinafine: a review of its use in onychomycosis in adults. Am J Clin Dermatol. 2003;4(1):39-65. Review.</citation>
    <PMID>12477372</PMID>
  </reference>
  <reference>
    <citation>Del Rosso JQ. The role of topical antifungal therapy for onychomycosis and the emergence of newer agents. J Clin Aesthet Dermatol. 2014 Jul;7(7):10-8. Review.</citation>
    <PMID>25053979</PMID>
  </reference>
  <reference>
    <citation>Dougherty PF, Yotter DW, Matthews TR. Microdilution transfer plate technique for determining in vitro synergy of antimicrobial agents. Antimicrob Agents Chemother. 1977 Feb;11(2):225-8.</citation>
    <PMID>848924</PMID>
  </reference>
  <reference>
    <citation>Elewski BE. Onychomycosis: pathogenesis, diagnosis, and management. Clin Microbiol Rev. 1998 Jul;11(3):415-29. Review.</citation>
    <PMID>9665975</PMID>
  </reference>
  <reference>
    <citation>Elewski BE, Rich P, Tosti A, Pariser DM, Scher R, Daniel RC, Gupta AK. Onchomycosis: an overview. J Drugs Dermatol. 2013 Jul 1;12(7):s96-103.</citation>
    <PMID>23884508</PMID>
  </reference>
  <reference>
    <citation>Elkeeb R, Hui X, Murthy N, Maibach HI. Emerging topical onychomycosis therapies - quo vadis? Expert Opin Emerg Drugs. 2014 Dec;19(4):489-95. doi: 10.1517/14728214.2014.975206. Epub 2014 Nov 17. Review.</citation>
    <PMID>25401504</PMID>
  </reference>
  <reference>
    <citation>Ely JW, Rosenfeld S, Seabury Stone M. Diagnosis and management of tinea infections. Am Fam Physician. 2014 Nov 15;90(10):702-10.</citation>
    <PMID>25403034</PMID>
  </reference>
  <reference>
    <citation>Gupta AK, Simpson FC. New pharmacotherapy for the treatment of onychomycosis: an update. Expert Opin Pharmacother. 2015 Feb;16(2):227-36. doi: 10.1517/14656566.2015.993380. Epub 2014 Dec 19. Review.</citation>
    <PMID>25522979</PMID>
  </reference>
  <reference>
    <citation>Matsuda Y, Sugiura K, Hashimoto T, Ueda A, Konno Y, Tatsumi Y. Efficacy Coefficients Determined Using Nail Permeability and Antifungal Activity in Keratin-Containing Media Are Useful for Predicting Clinical Efficacies of Topical Drugs for Onychomycosis. PLoS One. 2016 Jul 21;11(7):e0159661. doi: 10.1371/journal.pone.0159661. eCollection 2016.</citation>
    <PMID>27441843</PMID>
  </reference>
  <reference>
    <citation>Miettinen O, Nurminen M. Comparative analysis of two rates. Stat Med. 1985 Apr-Jun;4(2):213-26.</citation>
    <PMID>4023479</PMID>
  </reference>
  <reference>
    <citation>Müller G, Kramer A. Biocompatibility index of antiseptic agents by parallel assessment of antimicrobial activity and cellular cytotoxicity. J Antimicrob Chemother. 2008 Jun;61(6):1281-7. doi: 10.1093/jac/dkn125. Epub 2008 Mar 25.</citation>
    <PMID>18364400</PMID>
  </reference>
  <reference>
    <citation>Schnuch A, Geier J, Brasch J, Fuchs T, Pirker C, Schulze-Dirks A, Basketter DA. Polyhexamethylenebiguanide: a relevant contact allergen? Contact Dermatitis. 2000 May;42(5):302-3.</citation>
    <PMID>10789863</PMID>
  </reference>
  <reference>
    <citation>Schnuch A, Geier J, Uter W, Basketter DA, Jowsey IR. The biocide polyhexamethylene biguanide remains an uncommon contact allergen. Contact Dermatitis. 2007 Apr;56(4):235-9.</citation>
    <PMID>17343627</PMID>
  </reference>
  <reference>
    <citation>Thomas J, Jacobson GA, Narkowicz CK, Peterson GM, Burnet H, Sharpe C. Toenail onychomycosis: an important global disease burden. J Clin Pharm Ther. 2010 Oct;35(5):497-519. doi: 10.1111/j.1365-2710.2009.01107.x. Review.</citation>
    <PMID>20831675</PMID>
  </reference>
  <reference>
    <citation>Zeichner JA. Onychomycosis to Fungal Superinfection: Prevention Strategies and Considerations. J Drugs Dermatol. 2015 Oct;14(10 Suppl):s32-4. Review.</citation>
    <PMID>26461832</PMID>
  </reference>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>September 16, 2019</study_first_submitted>
  <study_first_submitted_qc>December 3, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 6, 2019</study_first_posted>
  <last_update_submitted>August 24, 2021</last_update_submitted>
  <last_update_submitted_qc>August 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>DSO</keyword>
  <keyword>Fungual Infection</keyword>
  <keyword>Fungus, Nail</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mycoses</mesh_term>
    <mesh_term>Onychomycosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Biguanides</mesh_term>
    <mesh_term>Polihexanide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

